NEUROONE™ MEDICAL TECHNOLOGIES CORPORATION

COMPANY OVERVIEW

High-definition, minimally invasive diagnostics & treatments for neurological disorders.

FORWARD LOOKING STATEMENT

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements may include statements regarding the Company's business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the SEC. These forward-looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market share and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

NeuroOne

TABLE OF CONTENTS

NeuroOne

ABOUT THE COMPANY

NeuroOne

Recently-formed, publicly-held, development stage medical device company

High-definition, minimally invasive diagnostics & treatments for neurological disorders including:

- Epilepsy
- Parkinson's Disease
- Essential Tremor
- Dystonia

STRATEGY & TACTICS

Develop and commercialize leading edge diagnostic & treatment products

- Create “comprehensive surgical system” technology
- Robust and growing IP portfolio
- Partner with world class physicians and scientists at leading institutions

Initial focus on the Epilepsy Market

- Target ~188 licensed epilepsy surgery centers
- Increase the total number of epilepsy surgeries each year

NeuroOne



THE MARKET NEED & OUR SOLUTION

Both patients and physicians are demanding improved diagnostic and treatment options

NeuroOne

EPILEPSY PATIENT DX - TX PATHWAY



NeuroOne

NEUROONE SOLUTIONS – A LEAP FORWARD

	Risk & Invasiveness	Recording Resolution	Brain Inflammation	Treatment Efficacy	Number of Surgeries
Current Tech	Full craniotomy – *pain, infection, etc.* 	Standard recordings are low resolution	High 	Per Cochrane review, 65% of surgical patients are seizure free at one year	**2 Brain Surgeries:** • 1 Diagnostic • 1 Therapeutic • Extended hospital stays
NeuroOne Solution	**Minimally invasive(in development)** 	**High definition:** detects micro seizures and single neuron activity 	Low 	Improved diagnostic recording should improve treatment efficacy	**Single Surgery:** Combination depth electrode diagnoses & treats; may enable bedside treatment and shorter hosptial stay

MARKET OPPORTUNITY — EPILEPSY ONLY[1]

	CURRENT MARKET – US ONLY[2]			ADDRESSABLE MARKET – US ONLY[2]		
PRODUCT	**NUMBER OF CASES**	**PRICE OF PRODUCT**	**ANNUAL REVENUES ($ millions)**	**NUMBER OF CASES**	**PRICE OF PRODUCT**	**ANNUAL REVENUES ($ millions)**
Cortical Diagnostic Film *or* Diagnostic Depth Electrode	16,000	$7,000[3]	112.0	720,000[3]	$8,400	6,000
MRI Compatible Surface Electrodes	800,000	$392[4]	313.6	1,000,000[5]	$431[6]	431
Combination Diagnostic and Ablation Depth Electrode	N/A	N/A	N/A	180,000[5]	$13,400	2,400
DBS System	2,000[5]	$50,000	100.0	120,000[5]	$50,000[7]	6,000
MI Cortical Diagnostic Film Delivery System	N/A	N/A	N/A	10,000[5]	$2,000[5]	20
			TOTAL $525.6			**TOTAL $14,851**

[1] The Company's focus is on epilepsy only at this time. Parkinson's Disease (250,000 cases annually) is a significant market, and Essential Tremors and Dystonia are smaller market opportunities.

[2] Based on data provided by Northland Securities Market Research. The European Market size is similar to the US Market size, with pricing approximately 20% lower.

[3] Based on Mayo Clinic physician data.

[4] Based on average of 28 electrodes used per procedure at $14 per electrode.

[5] Conservative estimate by NMTC management.

[6] Pricing is based on a 10% premium for MRI compatibility feature.

[7] Same pricing as current technology.

NeuroOne

THIN-FILM CORTICAL ELECTRODE

For use in iEEG or ECoG procedures – placed on the brain to record electrical activity



NeuroOne Advantages:

+ High definition, high quality recording improves diagnoses & treatment
+ Easily conforms to brain surface
+ Brain-friendly material addresses inflammation
+ Disposable cable and ZIF connector saves hospitals significant time & cost



Quick Facts:

Applications:
Epilepsy surgery and awake craniotomies

Competitors:
AdTech, PMT, Integra

Current Market:
$112M (inclusive of depth electrodes)

NeuroOne

MINIMALLY INVASIVE CORTICAL ELECTRODE DELIVERY SYSTEM

Converts standard full craniotomy to a small hole (1-1.5”) in the skull.



NeuroOne Advantages:

+ Tool enables minimally invasive electrode deployment
+ All the benefits of thin-film technology + MI delivery reduces trauma and recovery time
+ Currently, only NeuroOne thin-film technology can enable this technique
+ MI approach expands the epilepsy surgery market

Quick Facts:

Applications:
Enable new minimally invasive technique epilepsy surgery and awake craniotomies

Competitors:
N/A

Addressable Market:
$20M [additive to cortical electrode market]

NeuroOne

THIN-FILM DEPTH ELECTRODE

Same function & advantages as the cortical electrode in a tubular form that is robotically inserted into the brain (sEEG).



NeuroOne Advantages:

+ High definition, high quality recording improves diagnoses and treatment
+ Brain-friendly material addresses inflammation
+ Disposable cable and ZIF connector saves hospitals significant time & cost



Quick Facts:

Applications:
Epilepsy surgery and other awake brain mapping surgeries

Competitors:
AdTech, PMT, Integra

Current Market:
$112M [inclusive of cortical electrodes]

Other notes:
This minimally invasive diagnostic approach is new and quickly growing in the U.S. market

NeuroOne

COMBINATION DIAGNOSTIC + ABLATION DEPTH ELECTRODE

All-in-one device reduces Dx & Tx to a single procedure.



NeuroOne Advantages:

+ Single stage procedure for Dx & Tx
+ May provide bedside treatment capability saving significant time and cost
+ Thermal sensing capabilities allow surgeon to "test" ablation efficacy prior to lesioning tissue and preserve brain tissue
+ Overcomes laser drawbacks (lesion size, control, time/cost of procedure)



Quick Facts:

Applications:
Epilepsy

Competitors:
N/A
(aside from alternate epilepsy treatments such a lasers)

Addressable Market:
$2,400M

Other notes:
While sEEG is considered MI, treatment after diagnoses is often highly invasive and the benefit is lost– **this enables both Dx & Tx minimally invasive**

NeuroOne

DEEP BRAIN STIMULATION SYSTEM

Permanent implant to detect irregular brain activity and provide therapeutic stimulation.

NeuroOne Advantages:

+ Brain-friendly material addresses inflammation
+ Improved diagnostics improves electrode placement – key for treatment efficacy
+ Detection of microseizures should allow for improved responsive stimulation algorithms
+ Additional technology applications may be suitable for cardiovascular and spinal indications



Quick Facts:

Applications:
Parkinson's Disease, Epilepsy, Essential Tremor, Dystonia

Competitors:
NeuroPace, Medtronic, Boston Scientific, Abbott/SJM

Addressable Market:
$6,000M

Other notes:
DBS is primarily used in Parkinson's Disease. NeuroPace Responsive neurostimulation is the only DBS system for use in epilepsy.

NeuroOne

BRIDGING THE GAP —INTELLIGENCE(A.I).

+ Human brain consists of ~ 100 billion neurons

+ Damaged neurons cause a break in neuron to neuron connectivity responsible for deafness, blindness, paralysis and Parkinson's Disease

+ Successful treatments achieved by implanting small wires to record and reintroduce the natural signal back to the nerve across the damaged area

+ Elon Musk and others have started companies to try to implant millions of wires in the brain

+ Currently technology works – Cochlear, Second Sight, Argus II implants work on this principle – but is limited to 64 wires

+ NeuroOne's high-definition platform and advanced manufacturing processes will allow for high volume recording and stimulation of the neurons to bridge these gaps more effectively

INTELLECTUAL PROPERTY TO DATE

In-Licensed Patents From WARF At UW-Madison

PATENT NO.	ISSUE DATE	TITLE	ABSTRACT SUMMARY	OTHER INFORMATION
US 8,483,794	July 2013	Method for implanting an electrode that unfurls in response to a predetermined stimulus	Method of placing diagnostic film used for long-term stimulation and recording via a minimally invasive approach	Company and its patent counsel are planning new filings to update these cases. Per university patent filing protocol, foreign filings were not made on a timely basis, prior to NMTC obtaining these patent rights.
US 8,386,007	Feb 2013	Thin-film micro electrode array and method	Method and design for a long-term flexible electrode array for recording and stimulating on the the cortex utilizing a minimally invasive approach	Company and its patent counsel are planning new filings to update these cases. Per university patent filing protocol, foreign filings were not made on a timely basis, prior to NMTC obtaining these patent rights.
US 7,774,053	Aug 2010	Neural probe array	Design and spacing of an array of electrodes for subdural implantation capable of drug delivery through the apertures	Company and its patent counsel are planning new filings to update these cases. Per university patent filing protocol, foreign filings were not made on a timely basis, prior to NMTC obtaining these patent rights.

The Company has submitted patent applications to protect a variety of areas related to brain recording and therapeutic approaches

NeuroOne

THE NEUROONE TEAM

Meet our experienced managers and world class physicians, scientists, & partners

SCIENTIFIC ADVISORY BOARD

Greg Worrell MD, PhD, Chairman of the Scientific Advisory Board — World renowned neurologist at Mayo Clinic. Recognized by the American Epilepsy Society (AES), the American Academy of Neurology (AAN), the American Neurological Association (ANA), and the Citizens United in Research for Epilepsy (CURE) Foundation for his contributions to the field of epilepsy research. Dr. Worrell is a frequent keynote speaker at neurology conferences, and has published 90 papers.

Jamie Van Gompel, MD — Neurosurgeon practicing at Mayo Clinic, specializing in epilepsy surgery utilizing minimally invasive techniques. Dr. Van Gompel has authored or co-authored 87 papers since 2008.

Jorge Gonzalez, MD, PhD — Neurosurgeon practicing at The Cleveland Clinic, specializing in minimally invasive surgical techniques to treat epilepsy. Dr. Gonzalez has authored or contributed to almost 200 publications.

Greg Esper, MD, MBA — Associate Professor, Vice-President of Clinical Affairs, and Director of New Care Models in the Neurology Department at Emory University. Vice Chair of the Medical Economics and Management Committee for the American Academy of Neurology (AAN). Dr. Esper was Chair of the Navigating Health Reform Task Force for the AAN in 2012.

Justin Williams, PhD — Department Chair and Vilas Distinguished Achievement Professor at University of Wisconsin. Dr. Williams is credited with multiple publications, patents, and research in the field of thin-film electrodes for neurological recording, ablation, and stimulation.

NeuroOne

KEY MANAGERS

Dave Rosa — President and Chief Executive Officer

An entrepreneur with three decades of experience in the medical device industry spanning a variety of technologies and products. In addition to CEO roles with early stage medical device companies, Mr. Rosa's background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised $200M in the capital markets. Mr. Rosa holds an MBA from Duquesne University, and a BS in Commerce and Engineering from Drexel University.

Mark Christianson — Vice President of Business Development and Marketing

In excess of 15 years of executive sales, sales management, marketing, and project management experience with development stage companies. Prior to NeuroOne, Mr. Christianson held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics and plastic surgery. He holds an accounting degree from Augsburg College.

Tom Bachinski — Chief Development Officer

Thirty years of experience in research and development, engineering, and product development of neuro-stimulation devices, sensors and controls in the neurological market. Mr. Bachinski's experience includes senior level engineering roles at Empi Inc. (acquired by Exos Corporation in 2005), Goodrich Aircraft Sensors Corporation, and other medical device companies. Currently an inventor on 73 patents, he has a BS in Engineering from the University of Wisconsin, and a Master's in Engineering and an MBA from the University of St. Thomas.

NeuroOne

BOARD OF DIRECTORS

Paul Buckman, Chairman of the Board — Mr. Buckman is currently the General Manager of LivaNova PLC, a London-based medical device manufacturer, publicly trading on the NASDAQ. The Company develops devices used for cardiac surgery, neuromodulation, and cardiac rhythm management. LivaNova was formed by a 2015 $2.7 billion merger between Houston, Texas-based Cyberonics, Inc., and Milan, Italy-based Sorin S.p.a. Mr. Buckman has been a co-founder, president, or CEO of a number of medical device companies. He has led many of these companies to successful exits. He is currently on the board of several public and private medical device firms. Mr. Buckman received a Master's degree in Business Administration and Finance and a BA degree in Business Administration from Western Michigan University.

Dave Rosa, President and Chief Executive Officer — (See Key Managers for Bio)

Suraj Kalia — Mr. Kalia is currently a Managing Director and Senior Research Analyst at Northland Capital Markets, where he covers the medical technology sector. He has over18 years of experience working in financial and health care industries with senior level positions at investment banking firms such as Piper Jaffray and others. Mr. Kalia has also been an Adjunct Professor of Finance, teaching MBA-courses on Investment Theory and Mergers and Acquisitions at the University of St. Thomas in Minneapolis. He holds a Master's of Business Administration in Finance from the University of St. Thomas, a Bachelor's degree in Chemical Engineering from the Indian Institute of Technology in Bombay, India, and a Master's in Chemical Engineering from Stevens Institute of Technology in Hoboken, New Jersey.

Jeffrey Mathiesen — Mr. Mathiesen is currently the Chief Financial Officer of Gemphire Therapeutics Inc., a publicly-held clinical-stage biopharmaceutical company. He has held executive positions with publicly-traded and privately-held companies dating back to 1993, including vice president and chief financial officer positions. Mr. Mathiesen also serves as a Director, Audit Committee Chairman and Nominating and Governance Committee Member of Sun BioPharma, Inc., a publicly-traded clinical-stage biopharmaceutical company. He received a B.S. in Accounting from the University of South Dakota and is a Certified Public Accountant.

FINANCIALS

NEUROONE CAPITALIZATION TABLE

Stockholder	Number of Shares	% Ownership
Wade Frederickson *Co-founder*	2,613,458	33.2
Mark Christianson *Co-founder & VP of Sales*	1,423,206	18.1
Mayo Clinic	859,976	10.9
Dave Rosa *CEO*	793,822	10.1
Tom Bachinski *Chief Development Officer*	215,453	2.7
Other NeuroOne Shareholders	1,713,806	22.1

FINANCIAL DATA SUMMARY

(As of 5/4/18)

Listed on OTC QB	NMTC
Price:	$4.07
90-Day Price Range:	$3.25-$4.40
Daily Volume – Last 30 Day Average:	2,887 shares
Market Capitalization:	$32.0 Million
Fully Diluted:	*$33.5Million*
Shares Outstanding:	7,864,994
Fully Diluted:	*8,230,710*
Shares in Float (estimate):	1,200,000
Cash:	$225,000
Long-Term Debt:	None
Monthly Cash Burn:	$225,000

CAPITAL RAISED TO DATE

INSTRUMENT	DATE CLOSED	AMOUNT RAISED	INTEREST RATE	DISCOUNT TO EQUITY RAISE	WARRANT COVERAGE
Series #1 Convertible Note	6/17	$1,625,000	8%	20%[1]	100%
Promissory Note	8/17	$253,000	None	20%[2]	75%
Series #2 Convertible Note	5/18	$1,490,000	8%	20%[1]	100%

[1] Mandatory convert upon an equity raise of $3,000,000 or greater.
[2] Converted into series 1 convertible note terms.

NeuroOne

INVESTMENT HIGHLIGHTS

+ Market opportunity is substantial and well-defined

+ Disruptive, patented technologies which:
  - Address a significant and unmet need
  - Offer the expectation of substantially improved outcomes
  - Meet the need to lower costs

+ The majority of NMTC's products require only U.S. FDA 510(k) approval

+ Leading and highly-recognized co-development partners including Mayo Clinic, Cleveland Clinic, Emory University, and Wisconsin Alumni Research Foundation (WARF) at UW–Madison

+ Experienced management team, Scientific Advisory Board, and Board of Directors

NeuroOne

CONTACT

Dave Rosa
President and Chief Executive Officer
daver@neurooneinc.com